Title |
Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures
|
---|---|
Published in |
Korean Journal of Pediatrics, February 2017
|
DOI | 10.3345/kjp.2017.60.2.50 |
Pubmed ID | |
Authors |
Jae Won Shin, Yun Seob Jung, Kyungsoo Park, Soon Min Lee, Ho Seon Eun, Min Soo Park, Kook In Park, Ran Namgung |
Abstract |
The aims of this study were to evaluate the safety and pharmacokinetics of levetiracetam (LEV) in neonates with seizures and to establish a population pharmacokinetics (PPK) model by using the software NONMEM. A retrospective analysis of 18 neonatal patients with seizures, who were treated with LEV, including 151 serum samples, was performed. The mean loading dose was 20 mg/kg, followed by a mean maintenance dose of 29 mg/kg/day. Seventeen neonates (94%) had seizure cessation within 1 week and 16 (84%) remained seizure-free at 30 days under the LEV therapy. The mean serum concentration of LEV was 8.7 µg/mL. Eight samples (5%) were found above the therapeutic range. No serious adverse effects were detected. In the PPK analysis for Korean neonates, the half-life was 9.6 hours; clearance, 0.357 L/hr; and volume of distribution, 4.947 L, showing differences from those in adults. LEV is a safe and effective option for the treatment of neonatal seizures with careful therapeutic drug monitoring. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 21 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 3 | 14% |
Professor | 2 | 10% |
Student > Ph. D. Student | 2 | 10% |
Student > Master | 2 | 10% |
Student > Doctoral Student | 1 | 5% |
Other | 4 | 19% |
Unknown | 7 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 24% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 14% |
Neuroscience | 2 | 10% |
Unspecified | 1 | 5% |
Biochemistry, Genetics and Molecular Biology | 1 | 5% |
Other | 0 | 0% |
Unknown | 9 | 43% |